These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20976201)

  • 1. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
    Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
    PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
    Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
    Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
    Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
    PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
    Yin Y; Manoury B; Fåhraeus R
    Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.
    Lista MJ; Martins RP; Billant O; Contesse MA; Findakly S; Pochard P; Daskalogianni C; Beauvineau C; Guetta C; Jamin C; Teulade-Fichou MP; Fåhraeus R; Voisset C; Blondel M
    Nat Commun; 2017 Jul; 8():16043. PubMed ID: 28685753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.
    Reznichenko O; Quillévéré A; Martins RP; Loaëc N; Kang H; Lista MJ; Beauvineau C; González-García J; Guillot R; Voisset C; Daskalogianni C; Fåhraeus R; Teulade-Fichou MP; Blondel M; Granzhan A
    Eur J Med Chem; 2019 Sep; 178():13-29. PubMed ID: 31173968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1.
    Apcher S; Komarova A; Daskalogianni C; Yin Y; Malbert-Colas L; Fåhraeus R
    J Virol; 2009 Feb; 83(3):1289-98. PubMed ID: 19019958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
    Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
    J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
    Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
    Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
    J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate-specific presentation of MHC class I-restricted antigens via autophagy pathway.
    Tovar Fernandez MC; Sroka EM; Lavigne M; Thermou A; Daskalogianni C; Manoury B; Prado Martins R; Fahraeus R
    Cell Immunol; 2022 Apr; 374():104484. PubMed ID: 35247713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition.
    Tellam J; Smith C; Rist M; Webb N; Cooper L; Vuocolo T; Connolly G; Tscharke DC; Devoy MP; Khanna R
    Proc Natl Acad Sci U S A; 2008 Jul; 105(27):9319-24. PubMed ID: 18591662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthesis of truncated polypeptides for immune surveillance and viral evasion.
    Cardinaud S; Starck SR; Chandra P; Shastri N
    PLoS One; 2010 Jan; 5(1):e8692. PubMed ID: 20098683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.
    Tellam JT; Zhong J; Lekieffre L; Bhat P; Martinez M; Croft NP; Kaplan W; Tellam RL; Khanna R
    PLoS Pathog; 2014 Oct; 10(10):e1004423. PubMed ID: 25299404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system.
    Angrand G; Quillévéré A; Loaëc N; Dinh VT; Le Sénéchal R; Chennoufi R; Duchambon P; Keruzoré M; Martins RP; Teulade-Fichou MP; Fåhraeus R; Blondel M
    Nucleic Acids Res; 2022 Nov; 50(20):11799-11819. PubMed ID: 36350639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
    Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
    Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.